ストックスクリーナーアプリを入手
2.17
6.90%
0.14
アフターアワーズ：
2.11
-0.06
-2.76%
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks
Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - CTPost
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates - Nasdaq
Milestone Pharmaceuticals Inc. SEC 10-K Report - TradingView
Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Thursday - Defense World
Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments - CNBCTV18
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - StockTitan
Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Can Milestone Pharma's Trial Data Of Etripamil Nasal Spray In AFib-RVR Win Investors' Hearts? - RTTNews
US FDA’s March Approval Candidates Take Aim At Established Markets - Citeline News & Insights
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - StockTitan
Milestone Pharmaceuticals Prepares for CARDAMYST Launch - TipRanks
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray - Marketscreener.com
Milestone Pharmaceuticals secures key patent for CARDAMYST By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals secures key patent for CARDAMYST - Investing.com India
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil - The Manila Times
Milestone receives notice of allawance from USPTO on etripamil nasal spray - TipRanks
Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9% - MarketBeat
Adversity is less terrifying than hope: Milestone Pharmaceuticals Inc (MIST) - SETE News
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
MISTMilestone Pharmaceuticals Latest Stock News & Market Updates - StockTitan
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - Yahoo Finance
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 - The Manila Times
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - StockTitan
Retail investors who hold 57% of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) gained 14%, institutions profited as well - Simply Wall St
Milestone Pharmaceuticals Inc (MIST) may enjoy gains as insiders got busy in the recent days - Knox Daily
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - The News Heater
Milestone Pharmaceuticals Inc (MIST) Stock: A Year of Highs and Lows - The InvestChronicle
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
BlackRock, Inc. Reduces Stake in Milestone Pharmaceuticals Inc - GuruFocus.com
What was Milestone Pharmaceuticals Inc (MIST)’s performance in the last session? - US Post News
Insider’s View: Deciphering Fangdd Network Group Ltd (DUO)’s Financial Health Through Ratios - The Dwinnex
Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term - Yahoo Finance
What is HC Wainwright's Forecast for MIST FY2029 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MIST - MarketBeat
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Citeline News & Insights
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research - BioPharma Dive
HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings - Defense World
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone - PR Newswire
Milestone Pharma Faces FDA Decision In MarchWill It Mean Heartbreak Or Happiness For Investors? - RTTNews
FY2029 Earnings Estimate for MIST Issued By HC Wainwright - Defense World
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones - ACCESS Newswire
Milestone gears up for CARDAMYST launch in 2025 By Investing.com - Investing.com Australia
Milestone gears up for CARDAMYST launch in 2025 - Investing.com
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC - The Manila Times
Game-Changing Heart Treatment Could Hit Market in 2025: Inside Milestone's Launch Strategy - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright - Defense World
0.61%
大文字化:
|
ボリューム (24 時間):